Literature DB >> 3932079

The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.

J Posner, A Bye, K Dean, A W Peck, P D Whiteman.   

Abstract

The pharmacokinetics of bupropion and 3 of its basic metabolites were determined in 8 young, healthy, male volunteers after single and multiple oral doses of bupropion. Plasma profiles were obtained: 1) after a single 100 mg oral dose of bupropion hydrochloride, 2) following administration of 100 mg 8-hourly for 14 days and 3) again after a single 100 mg dose 14 days later. Plasma concentrations of the parent drug and metabolites were determined by high-performance liquid chromatography. Saliva secretion and pupil diameters were measured, subjective assessments of sleep made using visual analogue scales and side effects, blood counts and biochemistry were monitored. After the first dose mean elimination half lives (t1/2) of bupropion, and metabolites I and II were 8, 19 and 19 h respectively. On repeated administration there was little accumulation of the parent drug and no evidence for induction of its own metabolism. Accumulation of I was consistent with its rate of elimination after single doses while that of II was greater than predicted with prolongation of t1/2 to 35 h. Metabolite III was barely detectable after single doses but its accumulation on multiple dosing was consistent with its long half life (35 h) determined on occasion 2. Saliva secretion was significantly reduced during the multiple dosing period but there were no complaints of dry mouth. Subjective assessments of sleep were not significantly altered though one subject reported vivid dreams. There were no other adverse reactions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932079     DOI: 10.1007/bf00547376

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses.

Authors:  A P Géradin; F V Abadie; J A Campestrini; W Theobald
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

2.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

3.  Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man.

Authors:  J Hunter; J D Maxwell; M Carrella; D A Stewart; R Williams
Journal:  Lancet       Date:  1971-03-20       Impact factor: 79.321

4.  Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection.

Authors:  T B Cooper; R F Suckow; A Glassman
Journal:  J Pharm Sci       Date:  1984-08       Impact factor: 3.534

Review 5.  Enzyme induction (second of three parts).

Authors:  T D Gelehrter
Journal:  N Engl J Med       Date:  1976-03-11       Impact factor: 91.245

6.  Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine.

Authors:  W G Rapeport; G T McInnes; G G Thompson; G Forrest; B K Park; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

7.  Changes in plasma -glutamyl transpeptidase activity associated with alterations in drug metabolism in man.

Authors:  J B Whitfield; D W Moss; G Neale; M Orme; A Breckenridge
Journal:  Br Med J       Date:  1973-02-10

8.  Perceptual changes with bupropion, a novel antidepressant.

Authors:  R E Becker; R L Dufresne
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

9.  Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects.

Authors:  J W Findlay; J Van Wyck Fleet; P G Smith; R F Butz; M L Hinton; M R Blum; D H Schroeder
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Review of placebo-controlled trials with bupropion.

Authors:  W W Zung
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

View more
  12 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies.

Authors:  Naoe Yamane; Zenzaburo Tozuka; Makiko Kusama; Kazuya Maeda; Toshihiko Ikeda; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2011-04-07       Impact factor: 4.200

Review 3.  Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.

Authors:  C Sánchez; J Hyttel
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 4.  Chirality and drugs used in psychiatry: nice to know or need to know?

Authors:  R M Lane; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

5.  Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.

Authors:  Andrea R Masters; Michael McCoy; David R Jones; Zeruesenay Desta
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-18       Impact factor: 3.205

6.  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Authors:  Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2016-01-22       Impact factor: 3.922

7.  Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Authors:  Andrea R Masters; Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

Review 8.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

9.  Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.

Authors:  Caifu Xue; Xunjie Zhang; Weimin Cai
Journal:  Pharmaceutics       Date:  2017-12-21       Impact factor: 6.321

10.  Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects.

Authors:  Hui Ma; Wenping Zhang; Xiaoying Yang; Yuxin Zhang; Shijie Wei; Hao Zhang; Yanni Ma; Hongwan Dang
Journal:  Med Sci Monit       Date:  2018-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.